These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 18786009)

  • 1. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
    Auerswald G; Kreuz W
    Haemophilia; 2008 Nov; 14 Suppl 5():39-46. PubMed ID: 18786009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
    Berntorp E; Archey W; Auerswald G; Federici AB; Franchini M; Knaub S; Kreuz W; Lethagen S; Mannucci PM; Pollmann H; Scharrer I; Hoots K
    Eur J Haematol Suppl; 2008 May; (70):3-35. PubMed ID: 18380871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates.
    Favaloro EJ; Bukuya M; Martinelli T; Tzouroutis J; Duncan E; Welldon K; Collecutt M; Aumann H; Thom J; Gilmore G
    Thromb Haemost; 2002 Mar; 87(3):466-76. PubMed ID: 11916080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis in von Willebrand disease.
    Berntorp E
    Haemophilia; 2008 Nov; 14 Suppl 5():47-53. PubMed ID: 18786010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemate P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience.
    Schramm W
    Haemophilia; 2008 Nov; 14 Suppl 5():3-10. PubMed ID: 18786006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative in vitro evaluation of six von Willebrand factor concentrates.
    Lethagen S; Carlson M; Hillarp A
    Haemophilia; 2004 May; 10(3):243-9. PubMed ID: 15086321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
    Frank RD; Kunz D; Wirtz DC
    Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemate P/Humate-P: a systematic review.
    Berntorp E
    Thromb Res; 2009 Nov; 124 Suppl 1():S11-4. PubMed ID: 19944255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study.
    Miesbach W; Krekeler S; Wolf Z; Seifried E
    Thromb Res; 2015 Mar; 135(3):479-84. PubMed ID: 25595881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.